Cancer

Discovery of how colorectal cancer drug works will help more patients

21 hours ago   |   San Diego Biotechnology

LA JOLLA-Colorectal cancer is a common lethal disease, and treatment decisions are increasingly influenced by which genes are mutated within each patient. Some patients with a...
Read more ...

FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL

1 day ago   |   Gene Therapy

Posted on: 4 August 2020, The U.S. Food and Drug Administration approved Tecartus , a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell...
Read more ...

Near-infrared photoresponsive drug delivery nanosystems for cancer photo-chemotherapy

1 day ago   |   Journal of Nanobiotechnology

Drug delivery systems based on nanomaterials have shown a promise for cancer chemotherapy; however, it remains a great challenge to localize on-demand release of anticancer...
Read more ...

Avelas Announces Top-Line Data Showing Pegloprastide Can Significantly Improve Cancer Detection in Real Time During Breast Cancer Surgery

2 days ago   |   San Diego Biotechnology   |   2 articles

SAN DIEGO-- breastcancer-Top-line data showed the planned re-excision rate for patients who underwent breast cancer surgery with pegloprastide was 6% ....
Read more ...

Priming HER2 breast cancer with a vaccine to improve PD-1 inhibition

2 days ago   |   Fierce Biotech   |   2 articles

Priming HER2 breast cancer with a vaccine to improve PD-1 inhibition aliu Tue, 08/04/2020 - 05:49
Read more ...

MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020

2 days ago   |   San Diego Biotechnology   |   3 articles

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ - MEI Pharma, Inc. , a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P...
Read more ...

Postdoctoral Fellow - Cancer Targets and New Drug Discovery - Sanford Burnham Prebys Medical Discovery Institute - La Jolla, CA

2 days ago   |   San Diego Biotechnology

The goal of this 2-year training program is to establish an innovative multi-thematic graduate student and postdoctoral training program to train the next...From Sanford...
Read more ...

MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T

MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T

2 days ago   |   Xconomy

A MorphoSys antibody drug developed for diffuse large B-cell lymphoma has won FDA approval , providing an alternative to cumbersome and risky CAR-T therapies to treat the...
Read more ...

Inhibiting Enzyme Helps Cancer Immunotherapy Work Better

2 days ago   |   San Diego Biotechnology


Read more ...

Fate Therapeutics, Inc.: Associate Scientist / Senior Research Associate, Cancer Immunotherapy

3 days ago   |   San Diego Biotechnology   |   3 articles

Fate Therapeutics, Inc.: Fate Therapeutics is seeking a highly motivated individual with expertise in immunology and cancer biology or related fields to join a...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It's a particularly pronounced problem for therapies employing... Read more ...

Interpreting the Human Genome's Instruction Manual

Interpreting the Human Genome's Instruction Manual

An artistic representation of gene regulating elements, which allow cells with the same genetic code to differentiate into many different tissues and play many varied roles in... Read more ...

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that... Read more ...

As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients... Read more ...

Kristin Persson Named Director of Berkeley Lab's Molecular Foundry

Kristin Persson Named Director of Berkeley Lab's Molecular Foundry

Kristin Persson Kristin Persson, a senior faculty scientist in the Energy Storage & Distributed Resources Division within the Energy Technologies Area at Lawrence Berkeley... Read more ...

Geothermal Brines Could Propel California's Green Economy

Geothermal Brines Could Propel California's Green Economy

Thermal mud pots at Controlled Thermal Resources' project site at the Salton Sea. Deep beneath the surface of the Salton Sea, a shallow lake in California's Imperial County... Read more ...

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs... Read more ...

CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage

CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage

CymaBay Therapeutics' investigational drug seladelpar succeeded in a late-stage trial in patients with primary biliary cholangitis , producing results that suggest it could... Read more ...

Conservation machine learning

Read more ...

Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment...

Technology, expertise from UK's Mucokinetica to accelerate repurposing of generic remedy nafamostat for COVID-19 oral, inhalation therapy SAN DIEGO, Aug. 6, 2020 /PRNewswire... Read more ...